Codes ATC:
L01XA02
EMLc
Indication
Osteosarcoma of bone and articular cartilage of unspecified sites
Code ICD11:
2C21.Z
INN
Carboplatin
Type de médicament
Chemical agent
Type de liste
Liste complémentaire
(EML)
(EMLc)
(EMLc)
Formulations
Parenteral > General injections > IV:
50 mg per 5 mL ;
150 mg per 15 mL ;
450 mg per 45 mL ;
600 mg per 60 mL
Sexe
Tous
Âge
Aussi recommandé pour les enfants
Équivalence thérapeutique
La recommandation concerne ce médicament spécifique
Renseignements sur le brevet
Patents have expired in most jurisdictions
Lire la suite
sur les brevets.
Résumé des preuves et recommandation du comité d'experts
Carboplatin was originally added to the complementary list of the EML in 2009 as a treatment of advanced ovarian cancer.
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for carboplatin on the complementary list of the EML and EMLc for use in treatment protocols for osteosarcoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's consideration of treatment protocols for osteosarcoma is attached.